CareDx reported a 25% year‑over‑year revenue gain and signaled a strategic pivot to cell‑therapy surveillance with its AlloHeme assay. Validation data from the ACROBAT observational trial showed AlloHeme, a cell‑free DNA sequencing test, can predict relapse in patients after allogeneic hematopoietic cell transplantation for AML and related disorders. Management cited the assay as central to the company's Transplant Plus strategy, while warning that a proposed Medicare local coverage determination could cut projected 2026 revenue by roughly $15 million if finalized.